The European Medicines Agency (EMA) has recommended the withdrawal of the marketing authorization for Tavneos (avacopan), stating that the drug’s benefits no longer outweigh its risks for treating active granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). The agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that the data provided by the manufacturer failed to demonstrate a sufficient clinical benefit to justify the drug’s safety profile.
Why is the EMA recommending the withdrawal of Tavneos?
The EMA’s decision stems from a review of the ADVOCATE clinical trial, which served as the primary basis for the drug’s initial approval. According to the EMA’s official assessment, the committee identified concerns regarding the long-term effectiveness of avacopan when used as an add-on therapy.
While initial data suggested the drug could help reduce the need for high-dose glucocorticoids in patients with ANCA-associated vasculitis, the CHMP determined that the evidence was not robust enough to support a positive benefit-risk balance. The agency noted that uncertainties remained regarding the drug’s ability to maintain remission effectively, leading to the conclusion that the clinical data did not adequately support its continued use in the European Union.
What does this mean for patients currently taking Tavneos?
Patients currently prescribed Tavneos should not stop treatment without first consulting their healthcare provider. The EMA advises that physicians should review the treatment plans of patients receiving avacopan to determine appropriate alternatives.
Because GPA and MPA are serious, life-threatening autoimmune conditions, transitioning to standard-of-care therapies—such as rituximab or cyclophosphamide combined with corticosteroids—is necessary to prevent disease flares. The EMA’s recommendation is currently being sent to the European Commission, which will issue a final, legally binding decision for all EU member states.
How does this compare to other regulatory decisions?
The regulatory status of avacopan has been inconsistent across different global markets. While the EMA has moved to withdraw authorization, the U.S. Food and Drug Administration (FDA) approved Tavneos in October 2021 for use as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis.
This creates a significant divergence in how regulators interpret the same clinical data. The FDA’s approval was based on the ADVOCATE trial findings, which the agency deemed sufficient to show that the drug provided a meaningful benefit in reducing corticosteroid exposure. In contrast, the EMA’s CHMP maintained a stricter interpretation of the trial’s secondary endpoints and long-term efficacy markers.
Key Takeaways
- Regulatory Status: The EMA’s CHMP has recommended the withdrawal of the marketing authorization for Tavneos (avacopan) in the EU.
- Primary Reason: Regulators determined that the clinical benefits of the drug do not outweigh its risks for treating GPA and MPA.
- Clinical Guidance: Patients are urged to contact their rheumatologists or specialists to discuss alternative treatment strategies.
- Global Discrepancy: The FDA continues to authorize the use of Tavneos in the United States, highlighting a major difference in regulatory requirements and data interpretation between the two agencies.
- Next Steps: The European Commission will make the final decision on the withdrawal, which will then be implemented across the European Union.